Purpose: Low tidal volume ventilation (LTVV) reduces mortality in acute respiratory distress syndrome (ARDS) patients. Understanding local barriers to LTVV use at a former ARDS Network hospital may provide new insight to improve LTVV implementation. Methods: A cohort of 214 randomly selected adults met the Berlin definition of ARDS at Harborview Medical Center between 2008 and 2012. The primary outcome was the receipt of LTVV (tidal volume of ≤6.5 mL/kg predicted body weight) within 48 h of ARDS onset. We constructed a multivariable logistic regression model to identify factors associated with the outcome. Results: Only 27% of patients received tidal volumes of ≤6.5 mL/kg PBW within 48 h of ARDS onset. Increasing plateau pressure (OR 1.11; 95% CI 1.03 to 1.19; p-value b 0.01) was positively associated with LTVV use while increasing PaO 2 :F I O 2 ratio was negatively associated (OR 0.75; 95% CI 0.57 to 0.98; p-value 0.03). Physicians documented an ARDS diagnosis in only 21% of the cohort. Neither patient height nor gender was associated with LTVV use. Conclusions: Most ARDS patients did not receive LTVV despite implementation of a protocol. ARDS was also recognized in a minority of patients, suggesting an opportunity for improvement of care.
Introduction
Acute respiratory distress syndrome (ARDS) is a common and devastating form of respiratory failure that affects 190,000 patients annually in the United States and has a mortality rate of 39% [1] . Despite 30 years of clinical trials and drug research, only a handful of interventions reduce mortality in ARDS patients [2] [3] [4] [5] . In 2000, the ARDS Network published the results of the landmark randomized controlled trial that demonstrated a 9% absolute reduction in mortality utilizing a low tidal volume ventilation (LTVV) strategy targeting a goal tidal volume ≤ 6 mL (mL) per kilogram (kg) of predicted body weight (PBW) and a goal plateau pressure (P plat ) b30 cm H 2 O [6] . This ventilation strategy is now termed "lung protective ventilation" and has become the standard of care for patients with ARDS. Many studies have confirmed the benefits of LTVV [7, 8] , and have suggested a timedependent mortality benefit from early utilization of LTVV [9] . Emerging evidence also suggests that LTVV may prevent incident ARDS in at-risk, critically ill patients [10] [11] [12] .
The adoption of lung protective ventilation strategies in clinical practice has been slow despite convincing evidence of the benefits of LTVV [13] [14] [15] [16] [17] [18] . Studies performed in the initial five years of the ARDS Network trial demonstrated only 40% of ARDS patients received appropriate LTVV therapy [19, 20] . Low rates of compliance with LTVV have prompted further examination of barriers to utilization and several barriers to LTVV use have already been described. Known barriers include mismeasurement or missing height (used to calculate predicted body weight), concern for patient discomfort or perceived need for greater doses of sedating medications despite evidence to the contrary [21, 22] , and physician failure to recognize ARDS [13, 19, 23, 24] . Factors associated with higher utilization of LTVV include a written protocol for delivery of appropriate ventilator settings and a closed ICU staffing model [19, 25] , both of which have been adopted at our institution.
Our primary aim was to describe patient and physician factors associated with the use of LTVV in patients meeting the Berlin Definition of ARDS [28] at our institution, over ten years since the original trial. We hypothesized that the proportion of ARDS patients who receive LTVV remains low at our academic center, despite significant institutional efforts to increase utilization.
Methods
The University of Washington institutional review board approved this study with waiver of informed consent.
Study population: ARDS cohort
We conducted a retrospective cohort study using a pre-existing registry of patients admitted to a Harborview Medical Center (HMC) intensive care unit (ICU) between January 1, 2008 and December 31, 2012, and selected a random sample of adult patients (≥18 years old) who received mechanical ventilation. Harborview Medical Center is an academic hospital with a level one trauma designation and a former ARDS Network contributing site. Our hospital is a unique location as a contributing site in the original ARDS Network trial and we have already adopted several mechanisms to increase utilization of LTVV. Our institution has implemented written ventilator protocols, and has improved access to the tools needed to measure height. Our initial tidal volume (V T ) is automatically set at 8 mL/kg PBW for all mechanically ventilated patients. If a patient develops ARDS, we have a dedicated order set for LTVV [26, 27] that allows the respiratory therapist to incrementally adjust the V T to 6 mL/kg PBW. We also operate in a "closed" ICU staffing model, which has been associated with delivery of lower tidal volumes [25] .
We identified patients who received mechanical ventilation via an endotracheal tube for at least 48 h, and then assessed for the presence of severe hypoxemia with a PaO 2 :F I O 2 ratio ≤300 mm Hg on two consecutive arterial blood gas (ABG) measurements for entry into the cohort. We then evaluated chest radiographs obtained within 24 h of the qualifying ABG. Study authors blinded to ventilator settings analyzed each radiograph, and 10% of the total radiographs were reviewed by two readers (LJS and CLH). A qualifying chest radiograph met Berlin criteria [28] with demonstration of new bilateral infiltrates. ARDS onset was defined as the latter time of either the second qualifying ABG or qualifying chest radiograph.
Definition of LTVV
We defined our primary outcome of LTVV as ventilation with tidal volumes (V T ) ≤6.5 mL/kg of predicted body weight (PBW) from values charted by respiratory therapists in our electronic medical record. A V T of 6.5 mL/kg PBW is consistent with that chosen by the ARDS Network when evaluating LTVV adherence, and permits for slight deviations from the goal of 6.0 mL/kg PBW that can happen due to miscalculations or rounding in practical use [19] . LTVV use was not dependent on ventilator mode in our study and thus patients receiving ventilation via a pressure controlled mode met criteria for LTVV if the delivered tidal volume was ≤6.5 mL/kg PBW. We also collected plateau pressures from values charted by respiratory therapists. We measured the number of cases that received a low tidal volume at the time of the first qualifying ABG, and then again at 24 h and 48 h after ARDS onset. Patients met criteria for our primary outcome if they received LTVV at any one of the three time points.
Since the original ARDSNetwork protocol included increases in tidal volume to 7-8 mL/kg PBW in cases of severe dyspnea as long as the P plat remained b 30 cm H 2 O, we included a post hoc analysis of patients who received V T ≤ 8 mL/kg PBW as a secondary outcome for this study.
Collection of covariates
We abstracted electronic medical record charts to obtain demographic data, physiologic variables, lab values, ventilator settings and ICU type. Ventilator data was collected at three different time points for this study. The first time point was at ARDS onset, as described above. The second time point was one calendar day after ARDS onset, and the third time point at two calendar days after. Since multiple ventilator settings are recorded clinically each day, we selected those settings with appropriate maximum and minimum values. For example, the maximum F I O 2 and positive end-expiratory pressure (PEEP) for that day was abstracted, with the minimum V T .
We reviewed admission and daily notes in the first 48 h after ARDS onset to identify the underlying ARDS risk factor(s). We also reviewed physician notes to assess for documentation of concurrent acute brain injury as a potential contraindication to the use of LTVV, and for acute cardiac events that could confound an ARDS diagnosis. We did not exclude patients with chart documentation of acute cardiac events. We also reviewed progress notes for interpretation of ABG and/or chest radiographs, documentation of respiratory failure and/or of an ARDS diagnosis by physicians and trainees. Documentation of Acute Lung Injury and the more general, "lung injury," were also considered equivalent to an ARDS diagnosis as this cohort existed prior to the current Berlin definition [28] .
Statistical analysis
We computed descriptive statistics for all study variables including binomial confidence intervals for proportions. Difference testing between groups was performed using two-tailed t-tests for means, MannWhitney nonparametric tests for medians, and chi-square tests for proportions, as appropriate. We performed a trend test to assess for changes in the use of LTVV over time. A p-value of b0.05 was considered significant. We used SAS statistical software for all analyses (SAS version 9.4; SAS Institute, Inc., Cary, NC). We anticipated that approximately 40% of ARDS patients would receive LTVV based on prior studies [14, 20] and that approximately 26% of patients with respiratory failure have ARDS in our area [1] . We therefore screened a random sample of 700 ventilated patients to obtain a sample size of 200 for this study.
We built a multivariable logistic regression model using five factors selected a priori (age, type of ICU, sepsis/pneumonia; PaO 2 :F I O 2 ratio; P plat ) to examine associations with the receipt of LTVV at any time within 48 h of ARDS onset. The PaO 2 :F I O 2 ratio and P plat were included in our model based on prior literature suggesting that LPV use is associated with worsening ARDS severity [14, 29] . We included admission to a medical ICU, as prior literature has shown that perceived barriers to LPV use may vary by ICU type and intensivist training background [30] . ARDS risk factors of pneumonia and sepsis were included in the model since we suspected pulmonary ARDS may differ from other ARDS risk factors [31] with different radiographic features [32, 33] , and could lead to potential associations with our outcome.
There are potential contraindications to the use LTVV per the ARDS Network trial protocol including a pH b7.15, PaO 2 b 55 mm Hg, RR N 40 breaths per minute, and/or co-morbid acute brain injury. We examined the subset of patients without these potential contraindications, collected at ARDS onset, to assess for the possible effect of these contraindications on the use of LTVV at our center.
Results

Patients enrolled
From 31,722 patients admitted to an ICU at Harborview Medical Center between 2008 and 2012, we randomly selected 700 adult (≥18 years of age) patients who were mechanically ventilated (Fig. 1 ). Of those, 255 patients (36%) were intubated for at least 48 h and had two consecutive ABG measurements with a PaO 2 :F I O 2 ratio ≤300 mm Hg, meeting our criteria for possible ARDS. We excluded fourteen patients with chronic respiratory failure, three with brain death on arrival, four with missing radiographs, and 20 with radiographs inconsistent with ARDS. The final study cohort included 214 patients with ARDS.
Patient characteristics
The cohort had a mean age of 55 ± 16 years, was predominately male (71%) and of white race (83%) as shown in Table 1 . We identified at least one ARDS risk factor in 95% of patients, with trauma found to be the most common risk factor (43%) at our center. Patient demographic and clinical characteristics significantly differed between those who did and did not receive LTVV (Table 1) . Patients who did receive LTVV were an average of seven years younger, and were more than twice as likely to be admitted to a medical ICU. Neither patient height or gender differed with the use of LTVV in our study. Mortality also did not differ significantly between groups in unadjusted analyses.
ARDS severity and ventilator management
At ARDS onset, 99% were on assist control, volume-cycled ventilation. Patients had a mean PaO 2 :F I O 2 of 199 ± 68, a mean P plat of 22.7 ± 5 cm H 2 O, and received a mean tidal volume of 8.0 ± 1.0 mL/kg PBW. Patients who received LTVV were twice as likely to have severe ARDS (PaO 2 :F I O 2 b 100), and also had higher mean PEEP.
Use of low tidal volume ventilation in ARDS
Use of LTVV was low, and only 8% (N = 16) of patients received a tidal volume of ≤6.5 mL/kg PBW at the time of ARDS onset, while 11% (N = 24) received tidal volumes N 9 mL/kg PBW (Fig. 2) . At 24 h, LTVV use increased to 15% (N = 30) of the cohort with tidal volumes reported (14 cases had missing ventilator data). At 48 h, LTVV use again increased to 26% (N = 45) of those with reported ventilator data (44 cases missing). Overall, only 27% (N = 58) ever received LTVV within 48 h after ARDS onset, and the rate of use did not significantly vary by year when examined yearly over the five year study period (p = 0.78).
Management of plateau pressure
Additional analyses were performed to describe airway pressures in the cohort, and to assess practical adherence to a goal P plat b 30 cm H 2 O in ventilator management of ARDS. Of the 58 patients who received a tidal volume ≤ 6.5 mL/kg PBW in this study, 30% (N = 18) had P plat above the goal of 30 cm H 2 O. Only 33% (N = 6) had the recommended decrease in tidal volume to meet the goal plateau pressure.
Use of tidal volumes ≤8 mL/kg PBW
We performed additional analyses to examine the outcome of protective ventilation with a larger V T of 8 mL/kg PBW. Overall, a greater proportion (N = 121, 57%) of ARDS patients received a V T of ≤8 mL/kg PBW with P plat b30 cm H 2 O over the 48 hour time period when compared to those who received V T ≤6.5 mL/kg PBW. Differences in ARDS severity were no longer statistically significant and severe ARDS patients represented 13% (N = 16) of those who received a V T ≤8 mL/kg PBW, compared to 17% (N = 16) of those who received N8 mL/kg PBW. There was a change in the distribution of ICU type when examining LTVV with V T ≤8 mL/kg PBW, with increased proportion of patients in the Neurologic ICU (22%), and a subsequent relative decrease in the Medical ICU (26%) when compared to the stricter 6.5 mL/kg PBW. Comparisons between groups for ARDS risk factors were also different with this larger tidal volume, and the proportion of sepsis was not different between the two groups (23% vs. 29%, p-value 0.27).
Recognition of ARDS and LTVV
Chart-documented recognition of ARDS was low; only 21% (N = 46) of ARDS patients had a physician document a diagnosis of ARDS. In univariate analyses, patients who received LTVV were more likely to have an interpretation of a chest radiograph documented in the admission or daily note (84% vs. 52%, p b 0.01), more likely to have documentation of the ABG (64% vs. 24%, p b 0.01), and more likely to have physician documentation of an ARDS diagnosis (67% vs. 4%, p b 0.01). Among patients with a physician diagnosis of ARDS, 81% (N = 37) received LTVV within 48 h of ARDS onset and nine patients (19%) did not. Fifty-two ARDS patients (24%) lacked even the simplest documentation of respiratory failure in the electronic chart.
Potential contraindications to LTVV in ARDS
When evaluating for potential contraindications to the use of LTVV to explain low rates of use, only 13% (N = 28) patients had one or more of the following; pH b 7.15, PaO 2 b55, RR N 40, or acute brain injury. Among the remaining 186 patients without a potential contraindication, only 20% (N = 38) received LTVV within 48 h of ARDS onset. We examined physician documentation for overlapping cardiac failure in ARDS as a potential confounder with the use of LTVV. Forty-nine patients (23%) had documentation of pulmonary edema, but the proportion did not differ between patients who received LTVV and those who did not (24% vs. 22%, p = 0.94). Thirty-five patients (16%) had documentation of heart failure or myocardial infarction (MI) in the electronic chart either as a diagnosis or in consideration. Again, the proportion of heart failure and MI did not differ between the groups of ARDS patients that received LTVV and those that did not (17% vs. 16%, p = 0.99).
Multivariable logistic regression
In multivariable analysis, the presence of sepsis and/or pneumonia was independently associated with LTVV use as shown in Table 2 . Milder cases of ARDS were associated with reduced LTVV use; for every 50 mm Hg increase in the PaO 2 :F I O 2 ratio, the likelihood of receiving LTVV was 25% lower. Higher P plat was also positively associated with LTVV use, with the odds of receiving LTVV increasing by 11% for every 1 cm H 2 O increase in P plat .
Discussion
We found that LTVV was infrequently used and often delayed in the 48 h after ARDS onset in our hospital, which is consistent with prior studies. We propose that while the utilization of LTVV is low at our institution, it may represent an overestimate to what happens in daily ICU practice in hospital settings outside of the ARDS Network. A Hawthorne effect is likely present at our center as a participating site in the former ARDS Network clinical trials with increased awareness of ARDS and the evidence supporting the use of LTVV. We also found that 100% of our cohort had a patient height measurement documented in the electronic medical record, and that neither patient height or gender was associated with LTVV use in our study. Despite all of these efforts, still only 27% of ARDS patients ever received guideline recommended LTVV therapy in our hospital.
Previous literature has suggested that physicians may not pursue low tidal volumes in patients with ARDS when plateau pressures are not high [34] , and some argue that a P plat b 30 cm H 2 O is safe [35, 36] . In our study, each one cm H 2 O increase in P plat was associated with an 11% increase in the odds of LTVV use, suggesting that physicians may target pressurelimits when managing the ventilator in ARDS at our institution. However, when we examined those patients with P plat N 30 cm H 2 O, only 33% underwent additional decrease in V T , and is inconsistent with a pressure-limited strategy at our institution. Subsequent studies have refuted the sole pressure-limited strategy, and demonstrated it does not convey the same mortality benefit as the dual volume-pressure limited strategy utilized in the ARDS Network trial [9, 37] . The concept of ventilator driving pressure described by Amato et al. combines the two metrics of V T and P plat with PEEP and may provide a bridge to this physician knowledge gap for the future [38] . Higher P plat is also related to increased severity of ARDS, and the association between LTVV use and P plat in our study may reflect increased recognition of more severe cases with an increased willingness to treat.
ARDS may have been under-recognized by physicians in our study, with even less recognition in mild cases of ARDS. Physician underrecognition of ARDS, with increasing likelihood of recognition in more severe cases of ARDS, has been described to be a barrier to LTVV use in prior studies [13, 29, 34, 39, 40] . LTVV use was associated with increased ARDS severity and with physician documentation of an ARDS diagnosis in our hospital. However, the LUNG SAFE study demonstrated that even when physicians correctly diagnose ARDS, high-quality and evidence-based therapeutics such as LTVV are not used [29] . Furthermore, while our institution does have a dedicated LTVV order set for ventilator management for ARDS, we do not have a process or mandate to increase use. Creating a ventilator protocol that empirically lowers tidal volumes in mechanically ventilated patients with an ARDS risk factor would certainly increase compliance with the LTVV protocol [12] , but would not address the underdiagnosis of ARDS by physicians and could lead to missed opportunities to initiative advanced ARDS therapeutics. Therefore, continued efforts to bridge the physician knowledge gap and increase ARDS recognition and the importance of LTVV are still needed.
The independent association between sepsis and LTVV use in our study is a newer finding, and recently demonstrated by Weiss et al. [41] . Several subphenotypes of ARDS have been described with sepsisassociated ARDS being the most common. This sepsis subphenotype may be easier for physicians to identify radiographically, leading to improved diagnosis and greater LTVV use [42] . However, the association with LTVV use may also be due to the Surviving Sepsis campaign recommendation that all severe sepsis cases requiring mechanical ventilatory support utilize a low tidal volume strategy, and is further reinforced via clinical protocols as is the case at our institution [43] .
Our study has several potential limitations. First, we used the Berlin criteria to define ARDS in our study. The Berlin definition lacks the cardiac limitations from the American European Consensus Conference definition and could lead to misclassification bias. However, we examined chart documentation by physicians for relevant terms such as pulmonary edema, acute heart failure, etc. Documentation of these diagnoses occurred in only a small minority of the cohort, and did not change the proportional use of LTVV. Additionally, physician documentation is an imperfect surrogate for physician recognition of ARDS. However, the majority of patients with a documented ARDS diagnosis did go on to receive LTVV and we believe it was important to reflect whether practicing physicians were identifying patients that were eligible for LTVV. This study was conducted at a single site in a patient population that included a large proportion of patients who were white, male, and/or victims of trauma. Thus, while our findings may be less generalizable to other settings in the United States, our unique location as a former ARDSNetwork site warrants study of barriers to LTVV use as we have implemented known positive interventions to increase its use. We required two consecutive ABG measurements for entry into the cohort, which may bias towards a more proactive ventilator management strategy given the frequency of ABGs drawn. This was done to ensure the patient truly suffered from hypoxemic respiratory failure and likely ARDS, and not under-resuscitation or under-treatment. If true, this bias would likely shift in favor of the outcome, and may mean that LTVV use is overestimated in our sample relative to the population as a whole.
Conclusion
We found the majority of ARDS patients at a single, academic center do not receive lung protective ventilation in the first 48 h after ARDS, and b 25% of patients had any mention of ARDS in their medical records. Our findings support the conclusion that ARDS often not managed according to standard of care practices and may be widely under recognized. Approaches that increase recognition of ARDS may lead to lower tidal volume ventilator strategies and improve outcomes.
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